Experimental tumor targeting with radiolabeled ligands

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2371-2377

  Buchsbaum, Donald J ^a,b  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Monoclonal antibodies; Peptides; Radioimmunotherapy; Radiolabeled ligands; Tumor targeting

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY I 125; MONOCLONAL ANTIBODY I 131;

ANIMAL EXPERIMENT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CONFERENCE PAPER; GENE TARGETING; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DEPTH DOSE; RADIOIMMUNOTHERAPY; TUMOR BLOOD FLOW; TUMOR LOCALIZATION; TUMOR VASCULARIZATION;

EID: 0031456776     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2371::aid-cncr6>3.0.co;2-e     Document Type: Conference Paper

References (94)

1. Halpern SE, Dillman RO. Problems associated with radioimmunodetection and possibilities for future solutions. J Biol Resp Mod 1987;6:235-62.
2. Goodwin DA. Pharmacokinetics and antibodies. J Nucl Med 1987;28:1358-62.
3. Fischman AJ, Khaw BA, Strauss HW. Quo vadis radioimmune imaging. J Nucl Med 1989;30:1911-5.
4. Sands H. Experimental studies of radioimmunodetection of cancer: an overview. Cancer Res 1990;50(suppl):809-13.
5. Schlom J, Horan Hand P, Greiner JW, Colcher D, Shrivastav S, Carrasquillo JA, et al. Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. Cancer Res 1990;50(suppl):820-7.
6. Goodwin DA. Strategies for antibody targeting. Antibody Immunoconjug Radiopharmaceuticals 1991;4:427-34.
7. McAfee JG, Neumann RD. Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms. Nucl Med Biol 1996;23:673-6.
8. Halpern SE, Abdel-Nabi H, Murray JL. Radioimmunoimaging. Quo vadis? Toward die imaging of tumor. J Nucl Med 1990;31:1436-8.
9. Colcher D, Minelli MF, Roselli M, Muraro R, Simpson-Milenic D, Schlom J. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 1988;48:4597-603.
10. Schlom J, Eggensperger D, Colcher D, Molinolo A, Houchens D, Miller LS, et al. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992; 52:1067-72.
11. Lee F-T, Scott A, Cebon J, Rettig WJ, Welt S, Old LJ. Specific targeting of tumor vascular endothelium antigen (endosialin) using radiolabeled monoclonal antibody FB5. J Immunother 1994;16:151.
12. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 1992;89:10832-6.
13. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995;1:1623-34.
14. Burrows FJ, Watanabe Y, Thorpe PE. A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. Cancer Res 1992;52:5954-62.
15. Ali SA, Warren SD, Richter KY, Badger CC, Eary JF, Press OW, et al. Improving the tumor retention of radioiodinated antibody: Aryl carbohydrate adducts. Cancer Res 1990;50: (suppl)783-8.
16. Zalutsky MR, Noska MA, Colapinto EV, Garg PK, Bigner DD. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl) benzoate. Cancer Res 1989;49:5543-9.
17. 2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation. J Nucl Med 1995;36:2276-81.
18. Quadri SM, Vriesendorp HM, Leichner PK, Williams JR. Evaluation of indium-111-and yttrium-90-labeled linker-immunoconjugates in nude mice and dogs. J Nucl Med 1993;34: 938-45.
19. Schuster JM, Garg PK, Bigner DD, Zalutsky MR. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate. Cancer Res 1991;51:4164-9.
20. Schlom J. Monoclonal antibodies: they're more and less than you think. In: Broder S, editor. Molecular foundations of oncology. Baltimore: Williams & Wilkins, 1991:95-134.
21. Horan Hand P, Calvo B, Milenic D, Yokota T, Finch M, Snoy P, et al. Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant. Cancer Immunol Immunother 1992;35:165-74.
22. Buchsbaum DJ, Wahl RL, Glenn SD, Normolle DP, Kaminski MS. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res 1992; 52:637-42.
23. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329:459-65.
24. 131I-labeled and T-cell antibodies. Cancer Res 1986;46:6223-8.
25. Andrew SM, Teh JG, Johnstone RW, Russell SM, Whitehead RH, McKenzie IFC, et al. Tumor localization by combinations of monoclonal antibodies in a new human colon carcinoma cell line (LIM1899). Cancer Res 1990;50:5225-30.
26. Blumenthal RD, Kashi R, Stephens R, Sharkey RM, Goldenberg DM. Improved radioimmunotherapy of colorectal cancer xenografts using antibody mixtures against carcinoembryonic antigen and colon-specific antigen-p. Cancer Immunol Immunother 1991;32:303-10.
27. Buchsbaum DJ, Brubaker PG, Hanna DE, Glatfelter AA, Terry VH, Guilbault DM, et al. Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies. Cancer Res 1990;50(suppl):993-9.
28. 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts. Int J Radiat Oncol Biol Phys 1990;18:1033-41.
29. 131I-labeled monoclonal antibody CC49. Cancer Res 1995;55(suppl):5881-8.
30. 131I-labeled CC49 MAb in athymic nude mice bearing LS174T colon cancer xenografts following bolus injection or continuous infusion. Proc Twelfth Intl Hammersmith Conf; Lesbos, Greece, May 23-26, 1995. Abstract.
31. Vriesendorp HM, Quadri SM, Andersson BS, Dicke KA. Hematologic side effects of radiolabeled immunoglobulin therapy. Exp Hematol 1996;24:1183-90.
32. Blumenthal RD, Kashi R, Sharkey RM, Goldenberg DM. Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability. Int J Cancer 1995;61:557-66.
33. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994;15: 42-52.
34. 2 fragment and whole IgG2a in human glioma xenografts. Cancer Res 1988;48:5701-7.
35. Sharkey RM, Weadock KS, Natale A, Haywood L, Aninipot R, Blumenthal RD, et al. Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. J Natl Cancer Inst 1991;83:627-32.
36. Milenic DE, Yokota T, Filpula DR, Finkelman MAJ, Dodd SW, Wood JF, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991;51:6363-71.
37. Blumenthal RD, Sharkey RM, Kashi R, Natale AM, Goldenberg DM. Influence of animal host and tumor implantation site on radioantibody uptake in the GW-39 human colonic cancer xenograft. Int J Cancer 1989;44:1041-7.
38. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-8.
39. 2, and Fab in tumors. Cancer Res 1989;49:5656-63.
40. 131iodine-labeled antibody for a colon cancer model. Cancer Res 1995;55(suppl):5811-6.
41. 2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med 1990;31:1035-44.
42. Adams GP, McCartney JE, Tai M-S, Oppermann H, Huston JS, Stafford WF III, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993;53:4026-34.
43. King DJ, Turner A, Farnsworth APH, Adair JR, Owens RJ, Pedley RB, et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 1994;54:6176-85.
44. Horan Hand P, Kashmiri SVS, Schlom J. Potential for recombinant immunoglobulin constructs in the management of carcinoma. Cancer 1994;73(suppl):1105-13.
45. H3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56:3055-61.
46. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55:3825-34.
47. 177Lu]α-[2-(4-aminophenyl)ethyl]-1,4,7,10-tetraaza-cyclodecane- 1,4,7,10-tetraacetic acid-CC49 Fab radioimmunoconjugate. Cancer Res 1995;55:5288-95.
48. Sung C, van Osdol WW, Saga T, Neumann RD, Dedrick RL, Weinstein JN. Streptavidin distribution in metastatic tumors pretargeted with a biotinylated monoclonal antibody: theoretical and experimental pharmacokinetics. Cancer Res 1994;54:2166-75.
49. Saga T, Weinstein JN, Jeong JM, Heya T, Lee JT, Le N, et al. Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. Cancer Res 1994;54:2160-5.
50. Le Doussal J-M, Chetanneau A, Gruaz-Guyon A, Martin M, Gautherot E, Lehur P-A, et al. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scinitigraphy and immune response. J Nucl Med 1993;34:1662-71.
51. Goodwin DA. Tumor pretargeting: almost the bottom line. J Nucl Med 1995;36:876-9.
52. Kusakabe K, Kanaya K, Sato S, Kato M, Mochizuki K, Hashizume S, et al. Accumulation enhancement of human monoclonal antibody HB4C5 to lung tumor xenografts by N-deglycosylation. J Nucl Med 1994;35:289-95.
53. 2 fragments of an anti-CEA murine monoclonal antibody (Immu-14). Nucl Med Biol 1995;22:425-35.
54. Goldenberg DM, Sharkey RM, Ford E. Anti-antibody enhancement of iodine-131 anti-CEA radioimmunodetection in experimental and clinical studies. J Nucl Med 1987;28: 1604-10.
55. Marshall D, Pedley RB, Boden JA, Boden R, Begent RHJ. Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model. Br J Cancer 1994;69:502-7.
56. Norrgren K, Strand S-E, Nilsson R, Lindgren L, Sjogren HO. A general, extracorporeal immunoadsorption method to increase the tumor-to-normal tissue ratio in radioimmunoimaging and radioimmunotherapy. J Nucl Med 1993;34:448-54.
57. DeNardo GL, Maddock SW, Sgouros G, Scheibe PO, DeNardo SJ. Immunoadsorption: an enhancement strategy for radioimmunotherapy. J Nucl Med 1993;34:1020-7.
58. Rowlinson G, Snook D, Busza A, Epenetos AA. Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration. Cancer Res 1987;47:6528-31.
59. Lee Y, Bullard DE, Wikstrand CJ. Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration. Cancer Res 1987;47: 1941-6.
60. Quadri SM, Malik AB, Chu HB, Freedman RS, Vriesendorp HM. Intraperitoneal indium-111-and yttrium-90-labeled human IgM (AC6C3-2B12) in nude mice bearing peritoneal carcinomatosis. J Nucl Med 1996;37:1545-51.
61. Rowlinson-Busza G, Bamias A, Krausz T, Epenetos AA. Uptake and distribution of specific and control monoclonal antibodies in subcutaneous xenografts following intratumor injection. Cancer Res 1991;51:3251-6.
62. 188Re-RC-160, a directly-radiolabeled somatostatin analogue. Int J Cancer 1996;65:1-8.
63. Goldenberg DM, Blumenthal RD, Sharkey RM. Biological and clinical perspectives of cancer imaging and therapy with radiolabeled antibodies. Semin Cancer Biol 1990;1:217-25.
64. Sung C, Shockley TR, Morrison PF, Dvorak HF, Yarmush ML, Dedrick RL. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res 1992;52:377-84.
65. Kuhn JA, Beatty BG, Wong JYC, Esteban JM, Wanek PM, Wall F, et al. Interferon enhancement of radioimmunotherapy for colon carcinoma. Cancer Res 1991;51:2335-9.
66. Guadagni F, Schlom J, Pothen S, Pestka S, Greiner JW. Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon. Cancer Immunol Immunother 1988;26:222-30.
67. 131I-CC49) when given in combination with γ-interferon. Cancer Res 1993;53:600-8.
68. Rowlinson G, Balkwill F, Snook D, Hooker G, Epenetos AA. Enhancement by γ-interferon of in vivo tumor radiolocalization by a monoclonal antibody against HLA-DR antigen. Cancer Res 1986;46:6413-7.
69. 111In-labeled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst 1988;80:160-5.
70. 131I-antibody therapy for metastatic colon cancer. Antibody Immunoconjug Radiopharmaceuticals 1995;8:75.
71. Roselli M, Guadagni F, Buonomo O, Belardi A, Vittorini V, Mariani-Costantini R, et al. Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. J Clin Oncol 1996;14:2031-42.
72. 131I-CC49 Mab plus alpha interferon (rlFNα) in breast cancer. J Immunother 1994; 16:162.
73. Raben D, Buchsbaum DJ, Khazaeli MB, Rosenfeld ME, Gillespie GY, Grizzle WE, et al. Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Gene Ther 1996;3:567-80.
74. Buchsbaum DJ, Raben D, Stackhouse MA, Khazaeli MB, Rogers BE, Rosenfeld ME, et al. Approaches to enhance cancer radiotherapy employing gene transfer methods. Gene Ther 1996;3:1042-68.
75. 2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector mediated gene transfer. J Nucl Med 1997;38:1221-9.
76. Goldsmith KT, Curiel DT, Engler JA, Garver RI Jr. Trans complementation of an E1A-deleted adenovirus with codelivered E1A sequences to make recombinant adenoviral producer cells. Hum Gene Ther 1994;5:1341-8.
77. Dion LD, Goldsmith KT, Garver RI Jr. Quantitative and in vivo activity of adenoviral-producing cells made by cotransduction of a replication-defective adenovirus and a replication-enabling plasmid. Cancer Gene Ther 1996;3:230-7.
78. Raben D, Buchsbaum DJ, Mikheeva G, Grizzle WE, Khazaeli MB Rogers B, et al. A strategy to augment efficacy of genetic radiation immunotherapy by use of conditionally replication-enabled adenovirus. Cancer Gene Ther 1996;3(suppl):31.
79. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50(suppl):814-9.
80. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990;9:253-66.
81. Jain RK. Haemodynamic and transport barriers to the treatment of solid tumours. Int J Radiat Biol 1991;60:85-100.
82. Sands H, Jones PL, Shah SA, Palme D, Vessella RL, Gallagher BM. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. Cancer Res 1988;48:188-93.
83. Shrivastav S, Schlom J, Raubitschek A, Molinolo A, Simpson J, Hand PH. Studies concerning the effect of external irradiation on localization of radiolabeled monoclonal antibody B72.3 to human colon carcinoma xenografts. Int J Radiat Oncol Biol Phys 1989;16:721-9.
84. Kalofonos H, Rowlinson G, Epenetos AA. Enhancement of monoclonal antibody uptake in human colon tumor xenografts following irradiation. Cancer Res 1990;50:159-63.
85. Wong JY, Williams LE, Hill LR, Paxton RJ, Beatty BG, Shively JE, et al. The effects of tumor mass, tumor age, and external beam radiation on tumor-specific antibody uptake. Int J Radiat Oncol Biol Phys 1989;16:715-20.
86. 2 fragment to subcutaneous human glioma xenografts using local hyperthermia. Cancer Res 1990;50:1803-9.
87. Khawli LA, Miller GK, Epstein AL. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer 1994;73(suppl): 824-31.
88. Neuwelt EA, Barnett PA, Hellstrom KE, Hellstrm I, McCormick CI, Ramsey FL. Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J Nucl Med 1994;35:1831-41.
89. Pedley RB, Boden JA, Boden R, Boxer GM, Flynn AA, Keep PA, et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 1996;56:3293-300.
90. 111In-labeled hapten to bifunctional antibody in human colon tumor xenografts. Cancer Res 1991;51:1515-20.
91. Scheinberg DA. Current applications of monoclonal antibodies for the therapy of hematopoietic cancers. Curr Opin Immunol 1991;3:679-84.
92. Chatal J-F, Peltier P, Bardies M, Chetanneau A, Thedrez P, Faivre-Chauvet A, et al. Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy? Eur J Nucl Med 1992;19:205-13.
93. Goldenberg DM. Monoclonal antibodies in cancer detection and therapy. Am J Med 1993;94:297-312.
94. Sharkey RM, Blumenthal RD, Goldenberg DM. Development of cancer radioimmunotherapy and its potential use as an adjuvant treatment. In: Goldenberg DM, editor. Cancer therapy with radiolabeled antibodies. Boca Raton: CRC Press, 1995:101-14.